{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=budesonide+oral+suspension", "query": { "intervention": "budesonide oral suspension" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=budesonide+oral+suspension&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T05:09:16.807Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02605837", "title": "A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Oral Budesonide Suspension (OBS)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "11 Years to 55 Years" }, "enrollment_count": 318, "start_date": "2015-12-07", "completion_date": "2019-02-15", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 77, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605837" }, { "nct_id": "NCT03245840", "title": "Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Budesonide oral suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "11 Years to 55 Years" }, "enrollment_count": 133, "start_date": "2017-10-05", "completion_date": "2022-04-26", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03245840" }, { "nct_id": "NCT05569421", "title": "A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Treatment A: BGF MDI HFO", "type": "DRUG" }, { "name": "Treatment B: BGF MDI HFA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 108, "start_date": "2022-10-11", "completion_date": "2023-04-14", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05569421" }, { "nct_id": "NCT01642212", "title": "OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Oral Budesonide Suspension (MB-9)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "11 Years to 40 Years" }, "enrollment_count": 93, "start_date": "2012-07-23", "completion_date": "2014-10-30", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Orange, California • San Diego, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01642212" }, { "nct_id": "NCT05505734", "title": "A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "BDA MDI", "type": "DRUG" }, { "name": "AS MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bond Avillion 2 Development LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 2516, "start_date": "2022-09-02", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 61, "location_summary": "Mobile, Alabama • Paradise Valley, Arizona • Tempe, Arizona + 50 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05505734" }, { "nct_id": "NCT06067828", "title": "A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate", "type": "DRUG" }, { "name": "Treatment B: Budesonide and Formoterol Fumarate", "type": "DRUG" }, { "name": "Treatment C : Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 171, "start_date": "2023-10-24", "completion_date": "2026-01-22", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 7, "location_summary": "Los Angeles, California • Tarzana, California • Torrance, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Anderson", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06067828" }, { "nct_id": "NCT04294641", "title": "Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic GVHD" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "PFT's", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "Steroid pulse (prednisone)", "type": "DRUG" }, { "name": "Voriconazole", "type": "DRUG" }, { "name": "Posaconazole", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Budesonide", "type": "DRUG" }, { "name": "Beclomethasone", "type": "DRUG" }, { "name": "Filgrastim", "type": "OTHER" }, { "name": "Pegfilgrastim", "type": "OTHER" }, { "name": "Erythropoietin", "type": "OTHER" }, { "name": "Transfusions", "type": "OTHER" }, { "name": "Oral/Skin biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-05-10", "completion_date": "2024-10-01", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 2, "location_summary": "Bethesda, Maryland • St Louis, Missouri", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04294641" }, { "nct_id": "NCT07358234", "title": "Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]", "type": "DRUG" }, { "name": "budesonide oral suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-04", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07358234" }, { "nct_id": "NCT06268301", "title": "A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Budesonide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2023-02-06", "completion_date": "2023-02-20", "has_results": true, "last_update_posted_date": "2024-12-02", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06268301" }, { "nct_id": "NCT06723756", "title": "A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Treatment A: BGF MDI HFO", "type": "DRUG" }, { "name": "Treatment B: BGF MDI HFA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 105, "start_date": "2025-01-23", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-09-27T05:09:16.807Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06723756" } ] }